Neoadjuvant Pembrolizumab and Carboplatin Plus Paclitaxel for Stage I Triple-negative Breast Cancer

After signing informed consent form (ICF) and confirmed eligibility, eligible patients with localized TNBC, node-negative status, and who have not previously received chemotherapy, targeted therapy, and/or radiotherapy for invasive breast cancer (N=30) will receive treatment with Pembrolizumab and Carboplatin plus Paclitaxel up to surgery as indicated below: * Pembrolizumab: 200 mg, every three weeks (Q3W), intravenously (IV) on day 1 (D1) of each cycle. * Carboplatin: area under the curve (AUC) 1.5 (maximum dose of 225 mg), IV on D1, D8 and D15 of each 21-days cycle. * Paclitaxel: 80 mg/m2, IV on D1, D8 and D15 of each 21-days cycle. The treatment is composed by 4 cycles of 21 days each (patients will be treated for a total of 84 days) and treatment will last until surgery. After treatment discontinuation (EoT), all patients will have a safety visit scheduled 28 days (± 7 days) after the last dose of study treatment, in order to follow up toxicities and changes in concomitant medication. Patients discontinuing the study treatment period will enter a post-treatment follow-up period during which survival and new anti-cancer therapy information will be collected every 12 weeks (± 7 days) after the safety visit until death, lost to follow-up, elective withdrawal from the study, or end of study (EoS), whichever occurs first.